Non-small Cell Lung Cancer Drugs Market by Type, Product, and Geography - Forecast and Analysis 2023-2027

Published: May 2023 Pages: 167 SKU: IRTNTR72354

Non-small Cell Lung Cancer Drugs Market Analysis Report 2023-2027:

The non-small cell lung cancer (NSCLC) drugs market size is estimated to grow at a CAGR of 9.25% between 2022 and 2027. The market size is forecast to increase by USD 15,936.89 million. The growth of the market depends on several factors, including the increasing prevalence and incidence of non-small cell lung cancer, the strong drug pipeline and recent drug approvals, and the availability of patient assistance programs.

This non-small cell lung cancer drugs market report extensively covers market segmentation by type (adenocarcinoma, squamous cell carcinoma, and large cell carcinoma), product (biologics, small molecule targeted therapy, and chemotherapy), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the Size of the Non-Small Cell Lung Cancer (NSCLC) Market Drugs Market  During the Forecast Period?

To learn more about this report, View Report Sample

Non-Small Cell Lung Cancer (NSCLC) Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

The increasing prevalence and incidence of non-small cell lung cancer are notably driving the market growth, although factors such as the high cost of non-small cell lung cancer treatment may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Non-small Cell Lung Cancer Drugs Market Driver

One of the key factors driving growth in the NSCLC drugs market is the increasing prevalence and incidence of non-small cell lung cancer. Globally, the prevalence of lung cancer has increased due to the rise in risk factors such as cigarette smoking, secondary smoking, air pollution, and occupational exposure. As per the American Cancer Society estimates, in 2021, there were approximately 235,760 new cases of lung cancer in the US, and an estimated 131,880 people were expected to die of this disease.

NSCLC accounted for 84% of the total number of lung cancer cases in the US in 2021. On the other hand, in Asian countries, rapid industrial development and sub-urbanization, and disease patterns are leading to the increased prevalence of non-small cell lung cancer. Such factors will be contributing to the non-small cell lung cancer drugs market growth during the forecast years.

Significant Non-small Cell Lung Cancer Drugs Market Trends

The introduction and approval of combination therapies are one of the key NSCLC drugs market trends fueling the market growth. Combination therapies are being developed due to the increase in drug resistance, which is one of the key non-small cell lung cancer drugs market trends. Combination therapy can reduce drug resistance as tumors are less likely to have resistance to multiple drugs.

In May 2020, Eli Lilly and Company received approval from the US FDA for its CYRAMZA (ramucirumab injection, 10 mg or mL solution), in combination with erlotinib, for the first-line treatment of people with metastatic NSCLC, with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. The introduction and approval of combination therapies are expected to drive market growth during the forecast period.

Major Non-small Cell Lung Cancer Drugs Market Challenge

The high cost of treatment will be a major challenge for the NSCLC drugs market during the forecast period. Non-small cell lung cancer can be treated by surgery, radiation therapy, chemotherapy, targeted therapies, and immunotherapy. The cost of vinorelbine can range from USD 23.62 to USD 29.50 for a supply of 1 milliliter and from USD 45.33 to USD 84 for 5 millimeters. The cost of cisplatin can range from USD 20.69 to USD 25.43 for a supply of 50 milliliters and from USD 69.15 to USD 92.50 for 200 millimeters.

Similarly, immunotherapy for non-small cell lung cancer may include immune checkpoint inhibitors such as OPDIVO, KEYTRUDA, TECENTRIQ, and IMFINZI. The overall cost of treatment, including diagnosis, hospitalization, outpatient office visits, and a monthly initial treatment phase, is USD 46,000 per patient. Hence, such high costs of cancer treatment are expected to negatively impact market growth during the forecast period.

Key Non-small Cell Lung Cancer Drugs Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Non-small Cell Lung Cancer Drugs Market Customer Landscape

Who are the Major Non-Small Cell Lung Cancer (NSCLC) Market Drugs Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AbbVie Inc.: The company offers non-small cell lung cancer drugs such as Telisotuzumab vedotin. The company conducts research and development, manufacturing, commercialization, and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals.

The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Innovent Biologics Inc.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Merck KGaA
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Non-small Cell Lung Cancer Drugs Market?

The market share growth by the adenocarcinoma segment will be significant during the forecast period. Adenocarcinoma cancer is formed in the glandular tissue that lines certain internal organs and produces and releases substances such as mucus, digestive juices, and other fluids into the body. Most cancers of the breast, lung, esophagus, stomach, colon, rectum, pancreas, prostate, and uterus are adenocarcinomas.

Get a glance at the market contribution of various segments View the PDF Sample

The adenocarcinoma segment was valued at USD 8,047.94 million in 2017 and continued to grow until 2021.  Adenocarcinoma can spread to other parts of the body. This happens when cancer cells break away from the tumor and travel throughout the body through the bloodstream or lymph nodes. This is called invasive adenocarcinoma. The cancer spreads depending on where the abnormal cells started. For example, pancreatic cancer usually spreads to the liver first. Breast cancer usually spreads to the lymph nodes first. Adenocarcinoma can also spread to the lungs, brain, bones, bone marrow, and other organs. Hence, such factors will contribute to the growth of the market in focus during the forecast period.

Which are the Key Regions for the Non-small Cell Lung Cancer Drugs Market?

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The rising incidence of risk factors such as cigarette smoking, air pollution, and radiation are leading to the high prevalence of non-small cell lung cancer in North America. For instance, according to the CDC, in the US, approximately 200,000 people are diagnosed with lung cancer each year. The high prevalence of non-small cell lung cancer in the region also prompts government organizations to raise awareness through lung cancer screening programs such as National Comprehensive Cancer Control Program (NCCCP) and National Tobacco Control Program.

Several organizations are taking initiatives to fund research in lung cancer. In November 2021, the Lung Cancer Research Foundation (LCRF) and AstraZeneca (AZ) announced five research grant awards totaling USD 900,000, which are focused on understanding epidermal growth factor receptor (EGFR) inhibitor and immunotherapy resistance; each project will receive USD 180,000 over a two-year period.

The outbreak of COVID-19 led to a slight decline in the growth of the non-small cell lung cancer drugs market in North America in Q1 2020, owing to the temporary halt in the research of new drugs for NSCLC treatment and reduced hospital and clinic visits owing to the imposition of stay-at-home orders. However, the resumption of normal industrial and commercial activities and expedited research programs for NSCLC drugs are expected to drive the growth of the non-small cell lung cancer drugs market in the region during the forecast period.

Segment Overview

The non-small cell lung cancer drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • Type Outlook (USD Million, 2017 - 2027)
    • Adenocarcinoma
    • Squamous cell carcinoma
    • Large cell carcinoma
  • Product Outlook (USD Million, 2017 - 2027)
    • Biologics
    • Small molecule targeted therapy
    • Chemotherapy
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • ROW
      • Australia
      • Argentina
      • Rest of the world

Parent Market Analysis

Technavio categorizes the global non-small cell lung cancer drugs market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent global pharmaceuticals market covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Our market research report has extensively covered external factors influencing the parent market growth during the forecast period.

 

Non-small Cell Lung Cancer Drugs Market Scope

Report Coverage

Details

Page number

167

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 9.25%

Market growth 2023-2027

USD 15,936.89 million

Market structure

Fragmented

YoY growth 2022-2023(%)

8.88

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 37%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck KGaA, Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., PharmaMar SA, Regeneron Pharmaceuticals Inc., Sanofi, and Takeda Pharmaceutical Co. Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View PDF Sample

What are the Key Data Covered in this Non-small Cell Lung Cancer Drugs Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the market between 2023 and 2027
  • Precise estimation of the market size and its contribution of the market in focus to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behaviour
  • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of market vendors

We can help! Our analysts can customize this market research report to meet your requirements. 

Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global non-small cell lung cancer drugs market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on global non-small cell lung cancer drugs market 2017 - 2021 ($ million)
    • 4.2 Type Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Type Segment 2017 - 2021 ($ million)
    • 4.3 Product Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Product Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Type

    • 6.1 Market segments
      • Exhibit 30: Chart on Type - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Type - Market share 2022-2027 (%)
    • 6.2 Comparison by Type
      • Exhibit 32: Chart on Comparison by Type
      • Exhibit 33: Data Table on Comparison by Type
    • 6.3 Adenocarcinoma - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Adenocarcinoma - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Adenocarcinoma - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Adenocarcinoma - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Adenocarcinoma - Year-over-year growth 2022-2027 (%)
    • 6.4 Squamous cell carcinoma - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Squamous cell carcinoma - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Squamous cell carcinoma - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Squamous cell carcinoma - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Squamous cell carcinoma - Year-over-year growth 2022-2027 (%)
    • 6.5 Large cell carcinoma - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Large cell carcinoma - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on Large cell carcinoma - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on Large cell carcinoma - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Large cell carcinoma - Year-over-year growth 2022-2027 (%)
    • 6.6 Market opportunity by Type
      • Exhibit 46: Market opportunity by Type ($ million)
      • Exhibit 47: Data Table on Market opportunity by Type ($ million)

    7 Market Segmentation by Product

    • 7.1 Market segments
      • Exhibit 48: Chart on Product - Market share 2022-2027 (%)
      • Exhibit 49: Data Table on Product - Market share 2022-2027 (%)
    • 7.2 Comparison by Product
      • Exhibit 50: Chart on Comparison by Product
      • Exhibit 51: Data Table on Comparison by Product
    • 7.3 Biologics - Market size and forecast 2022-2027
      • Exhibit 52: Chart on Biologics - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Data Table on Biologics - Market size and forecast 2022-2027 ($ million)
      • Exhibit 54: Chart on Biologics - Year-over-year growth 2022-2027 (%)
      • Exhibit 55: Data Table on Biologics - Year-over-year growth 2022-2027 (%)
    • 7.4 Small molecule targeted therapy - Market size and forecast 2022-2027
      • Exhibit 56: Chart on Small molecule targeted therapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Data Table on Small molecule targeted therapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 58: Chart on Small molecule targeted therapy - Year-over-year growth 2022-2027 (%)
      • Exhibit 59: Data Table on Small molecule targeted therapy - Year-over-year growth 2022-2027 (%)
    • 7.5 Chemotherapy - Market size and forecast 2022-2027
      • Exhibit 60: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 61: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 62: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
      • Exhibit 63: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)
    • 7.6 Market opportunity by Product
      • Exhibit 64: Market opportunity by Product ($ million)
      • Exhibit 65: Data Table on Market opportunity by Product ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 67: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 69: Chart on Geographic comparison
      • Exhibit 70: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 Germany - Market size and forecast 2022-2027
      • Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.9 China - Market size and forecast 2022-2027
      • Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.10 Canada - Market size and forecast 2022-2027
      • Exhibit 99: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 100: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 101: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 102: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.11 UK - Market size and forecast 2022-2027
      • Exhibit 103: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 104: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 105: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 106: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 107: Market opportunity by geography ($ million)
      • Exhibit 108: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 109: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 111: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 112: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 113: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 114: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 115: AbbVie Inc. - Overview
              • Exhibit 116: AbbVie Inc. - Product / Service
              • Exhibit 117: AbbVie Inc. - Key news
              • Exhibit 118: AbbVie Inc. - Key offerings
            • 12.4 Amgen Inc.
              • Exhibit 119: Amgen Inc. - Overview
              • Exhibit 120: Amgen Inc. - Product / Service
              • Exhibit 121: Amgen Inc. - Key offerings
            • 12.5 Astellas Pharma Inc.
              • Exhibit 122: Astellas Pharma Inc. - Overview
              • Exhibit 123: Astellas Pharma Inc. - Product / Service
              • Exhibit 124: Astellas Pharma Inc. - Key news
              • Exhibit 125: Astellas Pharma Inc. - Key offerings
            • 12.6 AstraZeneca PLC
              • Exhibit 126: AstraZeneca PLC - Overview
              • Exhibit 127: AstraZeneca PLC - Product / Service
              • Exhibit 128: AstraZeneca PLC - Key news
              • Exhibit 129: AstraZeneca PLC - Key offerings
            • 12.7 Bayer AG
              • Exhibit 130: Bayer AG - Overview
              • Exhibit 131: Bayer AG - Business segments
              • Exhibit 132: Bayer AG - Key news
              • Exhibit 133: Bayer AG - Key offerings
              • Exhibit 134: Bayer AG - Segment focus
            • 12.8 BeiGene Ltd.
              • Exhibit 135: BeiGene Ltd. - Overview
              • Exhibit 136: BeiGene Ltd. - Business segments
              • Exhibit 137: BeiGene Ltd. - Key offerings
              • Exhibit 138: BeiGene Ltd. - Segment focus
            • 12.9 Boehringer Ingelheim International GmbH
              • Exhibit 139: Boehringer Ingelheim International GmbH - Overview
              • Exhibit 140: Boehringer Ingelheim International GmbH - Business segments
              • Exhibit 141: Boehringer Ingelheim International GmbH - Key news
              • Exhibit 142: Boehringer Ingelheim International GmbH - Key offerings
              • Exhibit 143: Boehringer Ingelheim International GmbH - Segment focus
            • 12.10 Bristol Myers Squibb Co.
              • Exhibit 144: Bristol Myers Squibb Co. - Overview
              • Exhibit 145: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 146: Bristol Myers Squibb Co. - Key news
              • Exhibit 147: Bristol Myers Squibb Co. - Key offerings
            • 12.11 Eli Lilly and Co.
              • Exhibit 148: Eli Lilly and Co. - Overview
              • Exhibit 149: Eli Lilly and Co. - Product / Service
              • Exhibit 150: Eli Lilly and Co. - Key news
              • Exhibit 151: Eli Lilly and Co. - Key offerings
            • 12.12 F. Hoffmann La Roche Ltd.
              • Exhibit 152: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 153: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 154: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 155: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 156: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.13 Innovent Biologics Inc.
              • Exhibit 157: Innovent Biologics Inc. - Overview
              • Exhibit 158: Innovent Biologics Inc. - Product / Service
              • Exhibit 159: Innovent Biologics Inc. - Key offerings
            • 12.14 Merck KGaA
              • Exhibit 160: Merck KGaA - Overview
              • Exhibit 161: Merck KGaA - Business segments
              • Exhibit 162: Merck KGaA - Key news
              • Exhibit 163: Merck KGaA - Key offerings
              • Exhibit 164: Merck KGaA - Segment focus
            • 12.15 Ono Pharmaceutical Co. Ltd.
              • Exhibit 165: Ono Pharmaceutical Co. Ltd. - Overview
              • Exhibit 166: Ono Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 167: Ono Pharmaceutical Co. Ltd. - Key offerings
            • 12.16 Pfizer Inc.
              • Exhibit 168: Pfizer Inc. - Overview
              • Exhibit 169: Pfizer Inc. - Product / Service
              • Exhibit 170: Pfizer Inc. - Key news
              • Exhibit 171: Pfizer Inc. - Key offerings
            • 12.17 Takeda Pharmaceutical Co. Ltd.
              • Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Overview
              • Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Key news
              • Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 176: Inclusions checklist
                • Exhibit 177: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 178: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 179: Research methodology
                • Exhibit 180: Validation techniques employed for market sizing
                • Exhibit 181: Information sources
              • 13.5 List of abbreviations
                • Exhibit 182: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              non-small cell lung cancer drugs market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis